Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-10-22-Speech-2-015"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2002-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Medicinal products2
dcterms:Language	"es"^^xsd:language2
lpv:document identification number	"en.20021022.1.2-015"2
lpv:hasSubsequent	lp_eu:2002-10-22-Speech-2-0162
lpv:speaker	lp:Laura González Álvarez2
lpv:spokenAs	member; PETI (2002-01-17--2003-07-07)3 substitute; EMPL (2002-01-17--2003-07-07)3 member; EUL/NGL (1999-07-20--2003-07-07)3 member; Delegation for relations with the countries of Central America and Mexico (2002-02-07--2003-07-07)3 substitute; Committee on Women's Rights and Equal Opportunities (2002-01-17--2003-07-07)3 unknown; Izquierda Unida (1999-07-20--2003-07-07)3 member; Committee on the Environment, Public Health and Consumer Policy (2002-01-17--2003-07-07)3
lpv:translated text	"Mr President, I would like to thank the rapporteurs, since these are very difficult reports and it is not easy to balance the different interests. I agree with them that our main concern must be attention to and clear information for patients. Neither must we forget what the honourable Member said in relation to the budget of the Agency and the different agencies. This is a restrictive budget, and in the end those of us who continue to say that the European Union’s general budget is very low if it is to confront enlargement and the spending the new countries will generate will be proved right. Since I do not have much time, Mr President, I would like to stress certain aspects of the report: firstly, the guarantee that the officials, experts and authors of reports do not have financial or any other type of interest in the pharmaceutical industry. Secondly, something that has been said here on many occasions, the clear differentiation between publicity and information. The free database with different levels for users, health staff, companies and others is all very well. However, as has also been said here, not everybody has access to the Internet and not everybody knows English and the Member States will have to provide patients with other important types of information so that they can decide between effectiveness, side effects and counter-indications. A system of penalties for holders of authorisations who fail to comply with the directive, making the actions of the holder in question public. And an increase – as the rapporteurs have said – in the monitoring of pharmaceuticals, because the effects of medication do not end with authorisation, and furthermore there must be continued monitoring. Finally, Mr President, access to generic medications that reduce pharmaceutical spending should be facilitated and furthermore there should be a guarantee that the Member States will provide information explaining to users that a cheaper medication is not necessarily any less effective."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph